Wealthfront Advisers
UTHR icon

Wealthfront Advisers’s United Therapeutics UTHR Stock Holding History

Wealthfront Advisers’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$483K Sell
892
-23
-3% -$13K ﹤0.01% 875
2026
Q1 		$543K Buy
915
+140
+18% +$69.7K ﹤0.01% 817
2025
Q4 		$378K Sell
775
-14
-2% -$6.52K ﹤0.01% 876
2025
Q3 		$331K Sell
789
-64
-8% -$21.5K ﹤0.01% 887
2025
Q2 		$245K Sell
853
-6
-0.7% -$1.79K ﹤0.01% 910
2025
Q1 		$265K Sell
859
-26
-3% -$8.91K ﹤0.01% 863
2024
Q4 		$312K Buy
885
+9
+1% +$3.31K ﹤0.01% 830
2024
Q3 		$314K Sell
876
-29
-3% -$9.8K ﹤0.01% 828
2024
Q2 		$288K Buy
+905
New +$240K ﹤0.01% 816
2023
Q1 		– Sell
-795
Closed -$221K – 821
2022
Q4 		$221K Buy
+795
New +$201K ﹤0.01% 760
2022
Q1 		– Sell
-1,261
Closed -$272K – 818
2021
Q4 		$272K Buy
1,261
+172
+16% +$33.8K ﹤0.01% 698
2021
Q3 		$201K Buy
+1,089
New +$215K ﹤0.01% 687

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Wealthfront Advisers's UTHR Position: Q2 2026 in Review

Wealthfront Advisers reduced its United Therapeutics (UTHR) stake by 2.5% in Q2 2026, selling an estimated $13K and leaving 892 shares worth $483K. The position accounts for ﹤0.01% of the portfolio, ranked #875.

Wealthfront Advisers first reported a position in UTHR in Q3 2021 and has held it in 12 quarters since. The position peaked at $543K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Wealthfront Advisers held 892 shares of United Therapeutics worth $483K as of Q2 2026.
  • Wealthfront Advisers sold 23 United Therapeutics shares in Q2 2026, an estimated $13K.
  • United Therapeutics made up ﹤0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #875 holding.
  • Wealthfront Advisers first reported a position in United Therapeutics in Q3 2021 and has held it in 12 quarters since.
  • Wealthfront Advisers's United Therapeutics position peaked at $543K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.